84 results about "Rifamycin" patented technology

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

The invention features an ascending dose regimen for the administration of rifamycin-class antibiotics. The dosing regimen can be used to treat bacterial infections and diseases related to infection.

The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and / or the treatment of bone and joint infections, especially for the prophylaxis and / or treatment of osteomyelitis.

Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity.

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

The invention provides a sterilizing method of a spherical phaeocystis culture solution, and relates to a microalgae culture solution. The method comprises the following steps: centrifuging algae solution which grows to an exponential phase, and removing supernatant; carrying out gravity suspension on algae cells with an f / 2 culture medium, centrifuging, and removing supernatant, repeating twice, and carrying out gravity suspension on the algae cells with the f / 2 culture medium; adding SDS (sodium dodecyl sulfate) and antibiotics, wherein the antibiotics are clindamycin, azithromycin, gentamicin, kanamycin, streptomycin, cefotaxime, ampicillin and rifamycin; culturing under illumination, centrifuging the algae solution and removing supernatant during culturing, carrying out gravity suspension on the algae cells with the f / 2 culture medium, centrifuging and removing supernatant, removing residual SDS and the antibiotics, transferring into the f / 2 culture medium, and culturing under illumination; and selecting survival transferred algae solution which is treated with SDS and the antibiotics, and detecting whether bacteria exist or not after the transferred algae solution grows to the exponential phase. The method is convenient to operate, complex operations, such as bacterium separation and test on sensitivity to antibiotics and the like, are avoided, and long-term treatment of high-concentration antibiotics has good sterilization effect.

A method for imparting broad spectrum antimicrobial activity to a medical device. The medical device is sequentially contacted with a first antimicrobial component, such as an antiseptic, and thereafter with a second antimicrobial component, such as a mixture of antibiotics. The first component may be a guanidium compound, such as chlorhexidine. The second component may be a mixture of a tetracycline, such as minocycline, and a rifamycin, such as rifampin.

The present invention relates to a method of controlling the two-component regulatory system of bacteria, in particular to an amrE gene and / or an amkE gene or homologous genes of the amrE gene or the amkE gene, which improves the yield of antibiotics and other useful secondary metabolites.

The invention relates to a treating method for wastewater produced in production of rifamycin. The treating method comprises the following steps: (1) pretreating wastewater produced in production of rifamycin by using advanced oxidation technology; (2) subjecting oxidation effluent to coagulating sedimentation and carrying out filtering to remove sediments; (3) carrying out anaerobic biochemical treatment on effluent of filtering; and (4) subjecting anaerobic effluent to treatment via a biological contact oxidation process and adding salt-resistant COD-removing bacteria, wherein the salt-resistant COD-removing bacteria are Paracoccus sp. FSTB-2 and / or Pseudomonas stutzeri FSTB-5, and Paracoccus sp. FSTB-2 and Pseudomonas stutzeri FSTB-5 are preserved in China General Microbiological Culture Collection Center on June 1, 2015, with accession numbers of CGMCC NO. 10938 and CGMCC NO. 10940, respectively. According to the invention, the process of advanced oxidation, coagulating sedimentation, anaerobic biochemical treatment and biological contact oxidation is employed, and the specific salt-resistant COD-removing bacteria are added into a contact oxidation unit and can tolerate antibiotics in the wastewater, so high-efficiency stable removal of CODs in the wastewater is realized; and the treating method has the characteristics of simple process, high treating efficiency, low treating cost, etc.

The invention discloses an application of a rifamycin-nitroimidazole coupling molecule shown in formula I in restraining anaerobic flora. The rifamycin-nitroimidazole coupling molecule shown in formula I provided by the invention has a broad-spectrum antibacterial activity to anaerobion, has an activity to most pathogenic bacteria related to bacterial vaginosis, has a better in vitro antimicrobial activity than that of bacterial vaginosis drugs, such as, metronidazole and clindamycin, and has an excellent application prospect at the aspect of preventing and treating the bacterial vaginosis or the other related diseases caused by the anaerobion.

The invention features a method of delivering a drug to a diseased cell by linking the drug to a rifamycin derivative, compositions that include drug-rifamycin conjugates of the invention, and methods for treating disease using those compositions.

The invention discloses a preparation method for rifampin by using a micro-reaction apparatus. The method comprises the following steps (1) dissolving rifamycin oxazine in an organic solvent so as to obtain a homogeneous solution; (2) dissolving 1-methyl-4-nitropiperazine in an organic solvent so as to obtain a homogeneous solution; (3) respectively pumping the two homogeneous solutions obtained in the step (1) and the step (2) into the micro-reaction apparatus; and (4) collecting outflowing liquid which is a crude rifampin product. A micro-reactor has the characteristics of a great specific surface area, a high transmission rate, short contact time, a few by-products, strong heat transfer and mass transfer capability, rapid and direct amplification, high security, good operationality and the like. A micro-reaction system is a parallel system of a modular structure and has the characteristic of good portability; the system can be dispersively constructed in a place where a product is used and realizes on-site production and product supply, so portability of a chemical plant is realized indeed; moreover, production can be adjusted by increasing or decreasing channel numbers and replacing modules according to market conditions, so the system has high operational flexibility.

The invention discloses a preparation method of a rifamycin-nitroiminazole coupled molecule. By using metronidazole as the raw material and changing the synthesis route, the preparation method overcomes the defect that the reaction condition must be controlled at low temperature, and enhances the yield of the target product.

The invention discloses application of a rifamycin-nitroimidazole coupling molecule represented in a formula I in inhibition of anaerobic or facultative anaerobic ammonia producing floras in gastrointestinal tracts. The rifamycin-nitroimidazole coupling molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low spontaneous drug resistance frequency and has very good application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant anaerobic bacteria. The formula is as shown in the specification.

The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

The present invention discloses a novel application of rifamycin-nitroimidazole coupling molecule and belongs to the field of medicinal chemistry. The rifamycin-nitroimidazole coupling molecule shows high activity to drug-resistant strains in the treatment of undistinguishable Clostridium, Helicobacter pylori infection related diseases, not only has antibacterial resistant activity to the rifamycin single drug-resistance bacteria and metronidazole single drug-resistance bacteria, but also has antibacterial activity against rifamycin resistant and metronidazole double drug-resistance bacteria; and the activity of the coupling molecule is superior to that of the composition of rifampicin and metronidazole in the molar ratio of 1:1.

Selective enrichment media and methods for selectively growing and detecting Salmonella spp. The media comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. The selective agents and efflux pump inhibitors are provided in the media in combinations and amounts that inhibit growth of non-Salmonella microorganisms without substantially affecting growth and metabolism of Salmonella species. Methods of selectively growing and detecting Salmonella species are provided.

The present invention provides an anti-tuberculosis gel preparation, which belongs to the technical field of ultrasonic therapy. The anti-tuberculosis gel preparation comprises, on the basis of dosage percentage, 0.5 to 8% of hydrophilic polymer materials, 0.5 to 15% of penetration enhancers, 2 to 10% of humectants, 0.5 to 3% of isoniazid, 2 to 5% of rifamycin and water. The preparation method for the gel preparation comprises the following steps: 1, preparing the components of gel preparation in proportion; 2, immersing the hydrophilic polymer materials in water to dissolve the materials; 3, adding the penetration enhancers and humectants into the obtained solution and carrying out stirring until the penetration enhancers and humectants dissolve; 4, adding isoniazid and rifamycin into the solution and carrying out uniform mixing under stirring. When used for ultrasonic medicine phoresis therapy, the gel preparation can guarantee that carried drug components smoothly penetrate into bodies to exert pharmacological effects and treat tuberculosis, besides exerting an effect of ultrasonic coupling.

The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R1 is a radical selected between hydrogen and alkyl; R2 is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R3 is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; the substituents of the phenyl of R2 and R3 selected from halogen, (C1-C4)-alkyl and (C1-C4)-alkoxyl and R4 is selected from hydrogen, alkyl allyl and homoallyl, they are useful for the treatment of mycobacterial infections, in particular for the treatment of infections produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium kansasii.

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

The invention relates to an externally applied preparation for treating whelks. The externally applied preparation is prepared by dissolving one or several medicaments of erythrocin, aureomycin, chloramphenicol, lincomycin hydrochloride, tobramycin, natamycin, norfloxacin, rifampicin, cyclosporine, gentamicin and neomycin into a polysaccharide aqueous solution. An obtained solution contains 0.005-1 wt% of medicaments and 0.01-30 wt% of glucan, xyloglucan, mycose, sea-tangle polysaccharides, tamarind gum, pectin or other Chinese medicinal herb polysaccharides, or a proper quantity of glucose, sodium chloride and potassium chloride are added to the aqueous solution to prepare a plaster preparation. The externally applied preparation has quick effect and definite curative effect on the whelks or acne and has small stimulation to the skin, extremely light skin decrustation degree and no obvious toxic or side effects. The process of the preparation can guarantee the chemical stability of each component in a production process.

The present invention is directed to 13C and / or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and / or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and / or condition), especially an autophagy mediated disease state and / or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and / or conditions, especially of the lung. Methods of treating autophagy disease states and / or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent / pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure / pharmacophore associated with an antibacterial agent.